|
71
|
| 243 |
IL1B
|
|
decreases_quantity of
|
NFKBIA
|
in cytosol; in cytokine treated cells
|
| 245 |
Troglitazone
|
|
increases_quantity of
|
NFKBIA
|
in cytosol; in cytokine treated cells
|
| 246 |
Ciglitazone
|
|
increases_quantity of
|
NFKBIA
|
in cytosol; in cytokine treated cells
|
| 247 |
PPARG
|
|
increases_quantity of
|
NFKBIA
|
in cytosol; if PPARG is overexpressed in cytokine treated cells
|
|
17521952
|
Diabetes mellitus, type I
|
|
230
|
| 953 |
abnormal astrocyte physiology
|
|
increases_expression of
|
NFKBIA
|
|
|
17515952
|
Epilepsy, temporal lobe
|
|
468
|
| 2231 |
Metformin
|
|
increases_quantity of
|
NFKBIA
|
in liver
|
|
15561958
|
Diabetes mellitus, type II
Insulin resistance
|
|
1,162
|
| 7723 |
NFKBIA
|
|
affects_activity of
|
NF-kappaB complex
|
in liver
|
| 7725 |
NFKBIA
|
|
affects_expression of
|
IL6
|
in LISR mice
|
| 7732 |
NFKBIA
|
|
affects_expression of
|
CD68
|
in liver; in LISR mice
|
| 7734 |
NFKBIA
|
|
affects_expression of
|
ADGRE1
|
in liver; in LISR mice
|
|
15685173
|
Diabetes mellitus, type II
Insulin resistance
|
|
1,293
|
| 8815 |
Fatty acid
|
|
decreases_quantity of
|
NFKBIA
|
in macrophage; in wild-type via increased degradation of NFKBIA
|
| 8816 |
TLR4
|
|
affects_quantity of
|
NFKBIA
|
in macrophage
|
|
17053832
|
Diabetes mellitus, type II
Insulin resistance
|
|
1,445
|
| 10145 |
IL1B
|
|
decreases_quantity of
|
NFKBIA
|
via increased degradation of NFKBIA
|
|
17038556
|
Diabetes mellitus, type II
Insulin resistance
|
|
1,581
|
| 11378 |
Chrysin
|
|
decreases_phosphorylation of
|
NFKBIA
|
in intestine
|
| 11379 |
Ellagic acid
|
|
increases_phosphorylation of
|
NFKBIA
|
in intestine
|
|
18377686
|
Diabetes mellitus, type II
Insulin resistance
|
|
1,592
|
| 11596 |
Genistein
|
|
decreases_expression of
|
NFKBIA
|
in inflamed cells
|
| 11634 |
NFKBIA
|
|
affects_activity of
|
inflammatory response
|
|
|
20816778
|
Diabetes mellitus, type II
Insulin resistance
|
|
1,663
|
| 12238 |
IL6R
|
|
affects_prenylation of
|
NFKBIA
|
in liver
|
|
20816090
|
Diabetes mellitus, type II
Obesity
Insulin resistance
|
|
1,679
|
| 12569 |
Palmitic acid
|
|
decreases_quantity of
|
NFKBIA
|
|
|
16798732
|
Diabetes mellitus, type II
Insulin resistance
|
|
1,850
|
| 14045 |
Obesity
|
|
decreases_quantity of
|
NFKBIA
|
in muscle
|
| 14058 |
Palmitic acid
|
|
decreases_quantity of
|
NFKBIA
|
in muscle
|
| 14060 |
Palmitic acid
|
|
increases_phosphorylation of
|
NFKBIA
|
in muscle
|
|
18633101
|
Diabetes mellitus, type II
Obesity
Insulin resistance
|
|
1,911
|
| 14646 |
high-fat diet
|
|
decreases_quantity of
|
NFKBIA
|
|
|
19116375
|
Diabetes mellitus, type II
Obesity
Insulin resistance
|
|
1,925
|
| 14917 |
high-fat diet
|
|
decreases_quantity of
|
NFKBIA
|
in hypothalamus
|
|
20808781
|
Diabetes mellitus, type II
Obesity
Insulin resistance
|
|
2,284
|
| 19460 |
stress, chronic interpersonal stress
|
|
increases_expression of
|
NFKBIA
|
|
|
19073750
|
Major depressive disorder
|
|
3,085
|
| 28320 |
Pioglitazone
|
|
increases_activity of
|
NFKBIA
|
|
|
14690537
|
Diabetes mellitus, type II
Parkinson disease
Insulin resistance
|
|
5,236
|
| 51015 |
Lipopolysaccharide
|
|
increases_phosphorylation of
|
NFKBIA
|
in vascular smooth muscle cells; resulting in increased activity of NF-kappa B
|
| 51016 |
NO
|
|
decreases_phosphorylation of
|
NFKBIA
|
in vascular smooth muscle cells; resulting in decreased activity of NF-kappa B
|
|
15194459
|
Metabolic
Cardiovascular disease
|
|
5,237
|
| 50997 |
NFKBIA
|
|
decreases_activity of
|
NF-kappaB complex
|
|
| 50998 |
response to oxidative stress
|
|
decreases_activity of
|
NFKBIA
|
via phosphorylation of IkappaB (IkappaB) and subsequent proteasomal degradation
|
|
15194459
|
Metabolic
Cardiovascular disease
|
|
6,140
|
| 57511 |
Resveratrol
|
|
increases_activity of
|
NFKBIA
|
via decreased phosphorylation
|
|
26124005
|
Colorectal cancer
Diabetes mellitus, type II
Insulin resistance
|
|
6,972
|
| 68441 |
I-kappa-B kinase complex
|
|
increases_phosphorylation of
|
NFKBIA
|
resulting in dissociation of NFKBIA from the NF-kappaB complex and subsequent activation of the complex
|
| 68442 |
I-kappa-B kinase complex
|
|
decreases_activity of
|
NFKBIA
|
|
| 68443 |
NFKBIA
|
|
decreases_activity of
|
NF-kappaB complex
|
via binding to the NF-kappaB complex
|
| 69049 |
NFKBIA
|
|
interacts (colocalizes) with
|
NF-kappaB complex
|
keeping the complex in an inactive state.
|
|
21252204
|
Inflammatory bowel disease
|
|
6,975
|
| 68398 |
NFKBIA
|
|
affects_activity of
|
Inflammatory bowel disease
|
|
|
24971461
|
Inflammatory bowel disease
|
|
7,044
|
| 69046 |
I-kappa-B kinase complex
|
|
increases_phosphorylation of
|
NFKBIA
|
in Jurkat cells; after induction with BCL10
|
|
|
Inflammation
|
|
7,082
|
| 69663 |
NF-kappaB complex
|
|
increases_expression of
|
NFKBIA
|
in U2OS cells
|
|
|
Inflammation
|
|
9,600
|
| 101513 |
GBP2
|
NOT |
affects_activity of
|
NFKBIA
|
|
|
21502320
|
Cancer
|
|
10,660
|
| 109129 |
DDRGK1
|
|
affects_activity of
|
NFKBIA
|
|
|
24921187
|
Diabetes mellitus, type II
Insulin resistance
|
|
10,823
|
| 110206 |
NFKBIA
|
|
affects_activity of
|
Myocardial infarction
|
|
|
31269974
|
Myocardial infarction
|
|
10,859
|
| 110552 |
RWDD3
|
|
increases_ubiquitination/sumoylation of
|
NFKBIA
|
|
|
27506944
|
Pancreatic neuroendocrine tumor
|
|
11,544
|
| 115390 |
RPS6KA1
|
|
increases_phosphorylation of
|
NFKBIA
|
|
|
30813401
|
Cardiovascular disease
|
|
12,906
|
| 123732 |
sex, aged female
|
|
decreases_expression of
|
NFKBIA
|
in aged female hearts; compared to young female hearts
|
| 123756 |
sex, young female
|
|
increases_expression of
|
NFKBIA
|
in young female hearts; compared to aged female hearts
|
|
30964749
|
Metabolic
|
|
13,489
|
| 127271 |
NFKBIA
|
|
affects_activity of
|
NF-kappaB complex
|
|
| 127272 |
protein phosphorylation
|
|
decreases_activity of
|
NFKBIA
|
|
|
32098346
|
Diabetes mellitus, type II
Insulin resistance
Nephropathy, diabetic
|
|
13,516
|
| 127461 |
Angiotensin (1-7)
|
|
decreases_activity of
|
NFKBIA
|
|
|
26536590
|
Diabetes mellitus, type II
Insulin resistance
|
CIDeRplus